文献速递白血病

超重急性髓系白血病患者化疗剂量减少的影响:一项丹麦全国队列研究

Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study.
PubMed 文献 · Br J Haematol · 2022-09-09

该丹麦全国队列纳入536例接受缓解诱导化疗的超重成人急性髓系白血病(AML)患者,其中10.1%被归为剂量减少(DR,即按体表面积全量给药剂量的95%或以下)。DR与非DR患者在完全缓解率、30天和90天死亡率、中位无复发生存期及中位总生存期上均无显著差异,但作者承认样本量有限并鼓励进一步研究。

要点

  • 超重AML患者中10.1%在诱导化疗时按体表面积剂量减少(≤95%全量)。
  • DR与非DR患者的完全缓解率、30天和90天死亡率均无显著差异。
  • DR与非DR的中位RFS、中位OS及5年限制性平均生存时间差值均无统计学显著差异。

核心结论

  • 在超重AML患者中,未发现剂量减少与结局之间存在统计学显著关联;作者承认样本量有限并鼓励在这一重要课题上进一步研究。

研究设计与样本

  • 丹麦全国队列研究,纳入536例接受缓解诱导化疗的超重成人AML患者,其中10.1%被归为剂量减少(定义为按体表面积全量给药剂量的95%或以下)。

主要发现

  • 剂量减少的风险因素为高体重指数(BMI)和高体表面积(BSA)、治疗相关AML及预后良好细胞遗传学。
  • DR与非DR患者完全缓解率、30天死亡率和90天死亡率均无显著差异。
  • 中位无复发生存期DR为14.5个月(95%置信区间9.0-41.7),非DR为15.0个月(12.3-19.3),调整后5年限制性平均生存时间差值(Δ5y-RMST)为0.2个月(-8.4至8.8)。
  • 中位总生存期DR为17.0个月(11.9至45.5),非DR为17.5个月(14.8至20.5),调整后Δ5y-RMST为0.8个月(-5.7至7.3)。

局限性

  • 作者承认样本量有限,并鼓励在这一重要课题上进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Overweight patients with cancer are frequently reduced in chemotherapy dose due to toxicity concerns, although previous studies have indicated that dose reduction (DR) of overweight patients results in comparable toxicity but may compromise overall survival (OS). Current evidence regarding DR in patients with acute myeloid leukaemia (AML) is limited. To investigate the association between DR and outcome among overweight patients with AML we analysed a Danish nationwide cohort of overweight adult AML patients treated with remission induction chemotherapy. Among 536 patients identified, 10.1% were categorized as DR defined as 95% or less of full body surface area (BSA)-based dose. Risk factors for DR were high body mass index (BMI) and BSA, therapy-related AML and favourable cytogenetics. No significant differences were observed for rates of complete remission (CR), 30- and 90-day mortality between DR and non-DR patients. Furthermore, DR did not affect median relapse-free survival (RFS) [DR, 14.5 (95% confidence interval, 9.0-41.7) months; non-DR, 15.0 (12.3-19.3)] with an adjusted difference in five-year restricted mean survival time (Δ5y-RMST) of 0.2 (-8.4 to 8.8) months nor median OS (DR, 17.0 [11.9 to 45.5] months; non-DR, 17.5 [14.8 to 20.5]) with an adjusted Δ5y-RMST of 0.8 (-5.7 to 7.3) months. In conclusion, we found no statistically significant association between DR and outcomes among overweight patients with AML. However, we acknowledge the limited sample size and encourage further studies in this important subject.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kristensen DT, Nielsen LB, Jakobsen LHK, et al. Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study. Br J Haematol. 2022. PMID: 36083781. doi:10.1111/bjh.18448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。